Chloroquine Against COVID-19 has generated more than frisson! If it was "just frisson" ... Like it or not, you need to read this text. Look. As attractive as it may be, even I, who already had my life in the hot seat on two trips to ICUs and medicines, and even after having spent a while using the DDI, I am aware of the risks and the order was:
Belly pain, stop the medication and come here immediately. A person in the ICU, intubated, is not very skilled in communication and his free will is very limited ...
Chloroquine IS NOT A Harmless Panacea for COVID-19
During a March 19 press conference, President Donald Trump announced that chloroquine, a drug long used to treat malaria, would be made available to those affected by COVID-19.
This accompanied the news of preliminary research, including a limited study in Australia, in which chloroquine has shown promise in eradicating coronavirus in some patients. An Chinese survey published in February suggested efficacy and safety of chloroquine in the treatment of pneumonia associated with COVID-19 - In Another ABA
A subsequent Chinese study involving the use of chloroquine and its molecular cousin, hydroxychloroquine, determined that hydroxychloroquine is the most potent of these two drugs in inhibiting this new coronavirus.
Stephen Hahn, MD, quickly clarified that larger studies are still needed
The controversy involved the president's announcement, especially after he indicated that chloroquine has already been approved for this use by FDA Agency commissioner Stephen Hahn, MD, quickly clarified that larger studies are still needed to determine the safety and efficacy of chloroquine in the treatment of COVID-19.
Much of the discussion that continued in the media throughout the day concerned the efficacy of the medication and, if so, how long it will take before this medication receives the green light for patient use.
While others are focusing on the drug's efficacy component in this debate, I am more concerned with safety regarding chloroquine. What I didn't see mentioned is the contraindication to the use of the medication in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
People with G6PD disabilities: Asymptomatic
However, many people with G6PD deficiency are asymptomatic and do not know they have it until something triggers an episode of hemolytic anemia. Common triggers include bacterial or viral infections and treatment with certain medications. A drug commonly associated with hemolytic anemia in G6PD deficiency is… chloroquine.
Should this be a concern in the current debate about the treatment of patients with COVID-19? In my opinion, yes. G6PD deficiency is quite common; in fact, it is the second most common human enzyme defect, affecting about 400 million people worldwide. It affects 1 in 10 African American men in the US It is quite common that it was written in an episode of the long-running TV series M * A * S *H. In this episode, the Cape Klinger character, of Mediterranean descent, became seriously ill after receiving an antimalarial drug. He was found to have hemolytic anemia and an association was made with the drug. The final credits included a brief commentary on the G6PD deficiency.
Given the challenges of knowing who may or may not be deficient in G6PD, it seems prudent not to use chloroquine in the treatment of patients with COVID-19 who may be at risk for this genetic condition. The last thing they need is to have a severe respiratory illness made up of hemolytic anemia, resulting in more loss of oxygen.
However, Contanto and meanwhile and Since…
Jackie Outed The Box! It's not up to you !!!
Hydroxychloroquine, on the other hand, does not induce hemolytic anemia in people with G6PD deficiency, despite the molecular similarity to chloroquine. He demonstrated effectiveness in inhibition of pandemic coronavirus during in vitro tests. Perhaps this is the drug the president and Hahn were referring to.
Hydroxychloroquine is where the FDA should direct its testing efforts and quickly to determine if this could be the silver bullet for the treatment of COVID-19.
Lack of serological awareness complicates the lives of people with HIV
People with HIV, or AIDS, should pay close attention to the speech of their infectologists and other health professionals involved in their treatments.
More about COVID and HIV
Disabled people. The link leads to important text, but outside the scope of the content on this page. Read it here!
Micobacterium Avium Complex: Learn More here!
Dan J. Vick, MD, DHA, MBA, CPE, pathologist and former hospital executive, he is a graduate faculty member of the Master of Health Administration Program at the Faculty of Health Sciences at Herbert H. & Grace A. Dow College of Health Professions at Central University Michigan, in Mount Pleasant.